In focus · trending topic

NMDA receptor antagonist

9 stories · following the connections

Otonomy Successfully Completes Open-Label Clinical Trial for OTIPRIO® in Patients with History of Otitis Media Requiring Tympanostomy Tubes

By Nasdaq OMXSep 15, 2016, 11:30 AM UTC

Otonomy Initiates Patient Enrollment in Second Phase 3 Clinical Trial of OTO-104 in Ménière’s Disease

By Nasdaq OMXMar 23, 2016, 11:30 AM UTC

Otonomy Announces Publication of OTIPRIO™ Phase 3 Clinical Trial Results in JAMA Otolaryngology

By Nasdaq OMXMar 18, 2016, 11:30 AM UTC

Otonomy Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update

By Nasdaq OMXMar 7, 2016, 9:14 PM UTC

Otonomy Initiates Phase 2 Clinical Trial of OTIPRIO™ in Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes

By Nasdaq OMXMar 3, 2016, 12:30 PM UTC

Otonomy Announces Commercial Availability of OTIPRIO™

By Nasdaq OMXMar 2, 2016, 12:30 PM UTC

Otonomy to Present at Cowen and Company Health Care Conference

By Nasdaq OMXFeb 29, 2016, 12:30 PM UTC

Otonomy to Report Fourth Quarter and Full Year 2015 Financial Results and Provide Corporate Update

By Nasdaq OMXFeb 26, 2016, 12:30 PM UTC